VIRAX BIOLABS GROUP LTD

LONDON, July 16, 2026 /PRNewswire/ – Virax Biolabs Group Limited (Nasdaq: VRAX) has published a shareholder update providing context on several recent developments, including the filing of its fiscal 2026 Annual Report, the multi-country commercial supply agreement with Fosun Diagnostics for ImmuneSelect across six Southeast Asian markets, the completion of a preferred investment option exercise generating approximately $3.3 million in gross proceeds, and the restoration of Nasdaq minimum bid price compliance. The update also outlines the Company’s priorities for ViraxImmune™, ImmuneSelect and continued commercial execution. Read the full Press Release here The post Virax Biolabs’ CEO James Foster Provides Shareholder Update Following Fiscal 2026 Annual Report and Fosun Diagnostics Commercial Supply Agreement appeared first on Virax Biolabs.

LONDON, July 09, 2026 /PRNewswire/ – Virax Biolabs Group Limited (NASDAQ: VRAX) (“Virax” or the “Company”) today announced that its wholly owned subsidiary, Virax Biolabs (UK) Limited, has entered into an exclusive multi-country commercial supply agreement with Fosun Diagnostics for the Company’s ImmuneSelect research-use immune profiling product line. The agreement covers six Southeast Asian markets, including Thailand, Vietnam, Indonesia, the Philippines, Singapore and Malaysia, and establishes a framework for immediate product supply under purchase orders, supporting near-term potential revenue opportunities and regional commercial expansion. Key highlights: Commercial supply agreement with Fosun Diagnostics covering six Southeast Asian markets, with exclusivity subject to agreed minimum purchase and performance requirements. Supports near-term potential revenue opportunities through purchase-order-driven supply of Virax’s commercially available ImmuneSelect product line Provides access to Fosun Diagnostics’ established regional commercial infrastructure and customer network. Framework supports expansion into additional products, higher-volume supply arrangements and potential OEM/private-label opportunities. Near-term commercial opportunity separate from ViraxImmune™, the Company’s in-development diagnostic platform. Read the full Press Release here The post Virax Biolabs Signs Multi-Country Commercial Supply Agreement with Fosun Diagnostics appeared first on Virax Biolabs.

LONDON, May 26, 2026 /PRNewswire/ — Virax Biolabs Group Limited (NASDAQ: VRAX) (“Virax” or the “Company”) today reported positive early pilot performance data for ViraxImmune™, its blood-based test in development for Long COVID, myalgic encephalomyelitis/chronic fatigue syndrome (“ME/CFS”) and related post-acute infection syndromes (“PAIS”). In the pilot dataset, ViraxImmune™ demonstrated measurable separation between PAIS patients and healthy controls, achieving 88% specificity and 92% positive predictive value (“PPV”) — early performance metrics that Virax believes support continued development and advancement into larger clinical validation… Read the full Press Release here The post Virax Biolabs Reports Positive Early Clinical Data for ViraxImmune™ in Long COVID and Related Post-Acute Infection Syndromes appeared first on Virax Biolabs.

T cell stimulation assays play an important role in modern immunology research. Not only are they useful tools in infectious disease and cancer immunotherapy studies, but they’re also critical aspects in various vaccine and drug development pipelines. Assays such as ELISpot, FluoroSpot and intracellular cytokine staining (ICS) are cornerstones of this effort, allowing researchers the opportunity to detect secreted biomarkers in vitro using patient-derived samples such as peripheral blood mononuclear cells (PBMCs).  While whole proteins, serum and live pathogens can all be used to trigger T cell activation, this is not a standardized method and is commonly associated with batch-to-batch variability. This approach can also activate other immune cell types non-specifically and induce uncoordinated cytokine release. They can introduce confounding factors into an experimental setup – such as endotoxins, immune system elements or unexpected viral/bacterial variants while also making it difficult to differentiate which epitopes are responsible for stimulation. It’s also worth noting the additional biosafety risks associated with live pathogens or serum – particularly in pipelines designed for cell therapy or drug development, where strict regulatory approval must be considered.12 Peptide pools are a game-changing technology when it comes to T cell stimulation research. While their concept and design are relatively simple, they offer superior specificity, robustness and ease of handling when compared to their live pathogen, serum or whole antigen counterparts. This article highlights the power of peptide pools in T cell research, exploring the mechanisms of T cell stimulation and the future of peptide pool applications. A closer look at T cell stimulation  While it’s easy to think of T cell stimulation as an all-or-nothing principle, it’s important to acknowledge the nuance and variability in this biological system. T cell responses (to a pathogen or antigen) are not haphazard reactions; in fact, they are highly specific, coordinated responses to small fragment regions of a foreign or stimulatory protein – not an entire organism or macromolecular structure. These small fragment regions, known as epitopes, are recognized through complementary binding to T cell receptors (TCR) on lymphocyte (T cell) surfaces. For a T cell to be activated, its TCRs must bind to specific epitopes and initiate a downstream intracellular signaling cascade. As TCRs themselves possess no inherent enzymatic activity, activation is mediated through protein kinases and ultimately transcription factor activity.3 Figure 1: A selection of peptide sequences from epitopes within a whole protein structure. TCRs recognize epitopes derived from both intracellular and extracellular pathogen proteins. Crucially, they don’t bind to the raw epitope sequence; instead, they bind to processed molecules presented on the surface of antigen-presenting cells (APCs).4 These APCs feature Major Histocompatibility Complex (MHC) molecules, specifically Class I and Class II. APCs first internalize and process the viral and bacterial epitopes before displaying them within the MHC binding cleft.5 Intracellular epitopes (like those from nuclear or cytosolic proteins) are typically presented on MHC Class I. Conversely, extracellular epitopes (such as those from capsid or vesicular proteins) usually present on MHC Class II, although there are through to be some limited exceptions. Both MHC Class I and MHC Class II presentations stimulate different T cell subtypes (CD8+ and CD4+ respectively). Figure 2: Major Histocompatibility Complex (MHC) Class I and Class II molecules. Not all epitopes are equally effective at eliciting a T cell response. In fact, all epitopes exhibit varying degrees of stimulatory signaling, also known as immunodominance. While the exact mechanisms underpinning immunodominance are still debated, some factors may include the re

Myalgic encephalomyelitis (ME/CFS), also known as chronic fatigue syndrome, is a complex condition characterized by post-exertional fatigue and a range of neuroimmune symptoms. It is one of several debilitating conditions that fall under the diagnostic umbrella of post-acute infection syndrome (PAIS) due to its association with an incomplete recovery from viral disease.  ME/CFS often presents with complexity and varying severity in the clinic. This means that it can be particularly difficult to diagnose, with approaches relying heavily on observational study and patient symptom self-reporting. While the diagnosis of ME/CFS is becoming easier as clinical awareness increases, challenges still remain due to the lack of a definitive and quantitative in vitro test.12 DecodeME and the Immunological Basis Of ME/CFS A major new study (DecodeME) led by the University of Edinburgh has revealed exciting new insights into the immunological components of ME/CFS with potential implications for future diagnostic development. The research, which supports the role of neuroimmune dysfunction in ME/CFS, reveals an association between key immune response and nervous system function genes and clinically validated ME/CFS presentations. The study, which analyzed the DNA of more than 15,500 people, identified eight specific genetic signals linked to the condition. Notably, several of these genetic variants were directly related to immune response and nervous system function, supporting long-standing clinical observations and patient-reported symptoms. Two of the discovered genetic variants were specifically tied to infection response mechanisms, further supporting the role of viral infection in ME/CFS pathogenesis. Supporting Blood-based Diagnostic Tests for ME/CFS While ME/CFS symptoms are varied, many experts believe that the key to a prospective in vitro diagnostic test could lie within patients’ blood.3 Immune cells – also known as T cells – reside within patients’ blood plasma and often show hallmark signs of dysfunction in cases of chronic fatigue. These dysfunctional changes, while yet to be fully elucidated, could be reflective of the genetic findings reported by DecodeME. Hence, the latest research further supports the potential for blood-based ME/CFS diagnostic testing and highlights the prospective role for T cell analysis in disease stratification and research. Translational Benefits of the Research The DecodeME study findings reinforce what many patients and clinicians have observed for years: unresolved infection can be a trigger for developing ME/CFS. Our ViraxImmune™ platform, which is currently being developed, is designed to explore these same questions from a different angle. We investigate the dysfunctions of the immune system, and specifically T cell response, which is critical in fighting off infections and managing chronic conditions. The DecodeME study’s results highlight the role of the immune system genes ,providing strong external validation for our in-development assay for the clinical diagnosis of PAIS. This assay could offer doctors and their patients unprecedented insights into adaptive immune dysfunction status, known to be associated with ME/CFS. By developing tools that help clinicians understand and manage post-viral immune dysfunction, we aim to provide better diagnostics and personalized treatment strategies. ** Want to learn more about ViraxImmune™? Subscribe to our newsletter for the latest updates and advancements. ** ** Caution Concerning Forward Looking Statements: This blog post contains forward-looking statements. In addition, from time to time, we or our representatives may make forward-looking statements orally or in writing. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance, including: our financial perfo